Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Simcere Collaborates with SIMM to Develop Novel COVID-19 Antiviral Therapy
Nanjing Simcere Pharma (HK: 2096) has formed a collaboration to develop novel antiviral drugs for COVID-19 with the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS). Specifically, Simcere has exclusive global rights to develop and commercialize a small-molecule antiviral that targets the 3C-like protease, a key enzyme in the replication and of coronaviruses. In preclinical animal models, SIM0417 showed good antiviral activity and safety against SARS-CoV-2. The two entities will work together to promote clinical research and marketing of the candidate.
No financial details of the agreement were released.
The companies said that, due to the 3CL protease's highly conserved nature, SIM0417 has a strong inhibitory effect on a variety of SARS-CoV-2 variants including the highly infectious Delta variant.
Mr. Ren Jinsheng, Chairman and CEO of Simcere, said, "R&D collaboration is one of our 'dual-track'-based R&D strategies. SIMM's powerful platforms and technologies for drug development have produced several novel drug candidates for COVID-19 during the pandemic. Simcere is committed to providing today's patients with the medicines of the future. We are very excited to work with CAS to develop this new generation of antiviral drugs and help further contribute
Earlier this year, Simcere in-licensed a clinical-stage therapy for Alzheimer's disease from
Simcere describes itself as transitioning to an innovation and R&D-driven pharmaceutical company. The company markets over 40 products in
See our other articles on Simcere.